Ketamine Rewires Neurons

Ketamine can act like a “reset button” for the Default Mode Network of the brain–the interconnected parts of the brain that are working when we’re not focused on anything else, and that may be responsible for much of the repetitive thoughts and narratives that give rise to many of our negative feelings. Ketamine can provide a “time-out” from this ordinary, usual mind, relief from negativity, an openness to the expansiveness of mind with access to the Self in the larger sense. These effects enhance a patient’s ability to engage in meaningful psychotherapy and integration during and after administration. Ketamine is a powerful agent for respite, analysis, and meditative presence, and a catalyst for recovery from depression and the lingering effects of trauma.

In addition, ketamine is also a catalyst for neurogenesis–boosting production of new neurons and heightening neuroplasticity. In other words, ketamine can literally, physiologically make your brain more receptive to new and better thought patterns, internal narratives, and life-giving habits–which makes it an ideal medicine to use in conjunction with therapy and integration.

science behind ketamine

Ketamine Journals and Articles

KAP is an effective method for decreasing depression and anxiety in a private practice setting. READ MORE
Overconsumption disorders such as harmful drinking, alcohol and substance use disorders (AUDs, SUDs), which represent leading causes of global preventable mortality and morbidity, are fundamentally acquired or learned behaviours. READ MORE
This was an uncontrolled open-label study in 20 patients who had been responders in an ascending dose ketamine study. The study was undertaken in a university clinic. Patients received one or two weekly ketamine doses of 1 mg/kg injected subcutaneously for 3 months. Data were collected from December 2015-June 2017. READ MORE
The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine works in the body and brain in persons with late-life treatment resistant depression. READ MORE

Depression frequently emerges during adolescence and is associated with severe outcomes. Current interventions do not lead to remission for many adolescents. Treatment-resistant depression (TRD) in adolescence is an ominous prognostic indicator for a lifetime of suffering and increased risk for suicide. READ MORE

This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine. READ MORE
Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the economy over $2 billion annually and represents a significant public health problem. This study aims to build on our discovery that a potent NMDA receptor antagonist, ketamine, has rapid (in hours) and robust therapeutic effects in OCD. The proposed projects test the acute mechanism of action of ketamine at the level of molecules, circuits, and network synchrony to determine how NMDA receptor antagonism modifies the underlying pathology of OCD to relieve repetitive thoughts and behaviors. READ MORE
Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) for alcohol use disorders. READ MORE

Ketamine is a prescription drug used for general anesthesia. In subanesthetic doses, it induces profound psychedelic experiences and hallucinations. The subanesthetic effect of ketamine was the hypothesized therapeutic mechanism in the authors’ use of ketamine-assisted psychotherapy for alcoholism. READ MORE

Lauren Silva of Forbes outlines recent psychedelic studies, interviews Michael Mithoefer, M.D., of MAPS Public Benefit Corporation (MAPS PBC), and emphasizes how “the FDA granted MDMA a breakthrough therapy designation for the treatment of post traumatic stress disorder (PTSD) to MAPS.”  READ MORE

NPR Podcasts

Get in Touch With Us

"*" indicates required fields

Contact Us
Call Us